Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
CORALVILLE, Iowa, Jan. 04, 2017 -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle, Ph.D., will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.
Details of KemPharm's presentation are as follows:
| Event: | Biotech Showcase 2017 | |
| Date: | Tuesday, January 10, 2017 | |
| Time: | 3:00 p.m. (Pacific Time) | |
| Location: | Hilton San Francisco Union Square |
The presentation will be webcast and available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system (CNS) disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release (ER) prodrug of methylphenidate for the treatment of attention deficit hyperactivity disorder (ADHD), and KP201/IR, an acetaminophen (APAP)-free formulation of the company’s immediate release (IR) abuse deterrent hydrocodone product, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
